Wholesale Orforglipron (LY3502970)

Orforglipron (LY3502970) is a first-in-class non-peptide, orally active GLP-1 receptor agonist currently in late-stage clinical development by Eli Lilly. Unlike peptide-based GLP-1 agonists such as semaglutide and tirzepatide, which require weekly subcutaneous injection and cold-chain storage, Orforglipron is a small molecule designed for once-daily oral administration — removing cold-chain constraints and simplifying research logistics significantly.

SARMs-Direct supplies wholesale Orforglipron in research-grade bulk quantities to CROs, pharmaceutical R&D groups, universities and qualified B2B distributors. All supply is strictly for research use only and is not available for human consumption or clinical use.

Orforglipron acts as a selective agonist at the glucagon-like peptide-1 (GLP-1) receptor — the same receptor targeted by the approved injectable agents semaglutide and tirzepatide. As a small molecule rather than a peptide, it bypasses the structural limitations that have historically confined GLP-1 agonists to injectable formats, making it the subject of significant pharmaceutical and academic interest.

Phase III clinical programmes have been investigating Orforglipron for weight management in adults with obesity and for glycaemic control in type 2 diabetes. Publicly reported data from earlier trials indicates double-digit mean weight reduction at higher doses in non-diabetic cohorts, alongside meaningful HbA1c reductions in diabetic populations. Tolerability profiles are consistent with the GLP-1 class — predominantly gastrointestinal adverse events including nausea, diarrhoea and constipation.

Its oral format removes cold-chain requirements, simplifying logistics for multi-site research programmes and reducing operational overhead compared with injectable alternatives.